Showing 2861-2870 of 7618 results for "".
- FDA Approves Adbry (tralokinumab-ldrm) for Treatment of Moderate-to-Severe AD in Pediatric Patients Aged 12-17 Yearshttps://practicaldermatology.com/news/fda-approval-of-tralokinumab-ldrm-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-pediatric-patients-aged-12-17-years/2462185/The US Food and Drug Administration (FDA) has expanded the approval of Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12 to 17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies
- Study: Implementing a Treat-to-Target Approach Can Benefit PsA Patientshttps://practicaldermatology.com/news/implementation-of-the-treat-to-target-approach-in-psoriatic-arthritis-and-its-outcomes-in-routine-clinical-practice/2462181/A new study published in Cureus showed measuring disease activity with validated tools and treating to target (T2T) in patients with psoriatic arthritis (PsA) is crucial to improving quality of life and better disease control. The first-ever retrospective review from
- Scinai Announces Promising Results in a Psoriatic Human Skin Modelhttps://practicaldermatology.com/news/scinai-announces-promising-results-in-a-psoriatic-human-skin-model/2462180/Scinai Immunotherapeutics Ltd. announced a successful preclinical trial result for its anti-IL-17 VHH antibody (NanoAb) as a local treatment for moderate plaque psoriasis. The study, designed to evaluate the anti-inflammatory effects of NanoAbs, used proprietary induced human
- Intradermal AIV001 Found Safe in Early BCC Studyhttps://practicaldermatology.com/news/intradermal-aiv001-found-safe-in-early-bcc-study/2462178/AiViva Biopharma Inc. completed its first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is intradermally administered and designed for local, prolonged treatment effect for dermatological conditions. The phase
- Kymera Update: First Patient Dosed in Phase 2 AD Clinical Trial of KT-474, a First-in-Class Investigational IRAK4 Degraderhttps://practicaldermatology.com/news/kymera-update-first-patient-dosed-in-phase-2-ad-clinical-trial-of-kt-474-a-first-in-class-investigational-irak4-degrader/2462177/The first patient has been dosed in the Phase 2 clinical trial (ADVANTA) evaluating KT-474 in AD, generating a $15 million milestone payment under its collaboration with Sanofi. KT-474 is an oral IRAK4 degrader, in development for the treatment of IL-1R/TLR-driven complex inflamma
- Study: Individuals With Acne Face Social and Professional Stigmahttps://practicaldermatology.com/news/study-individuals-with-acne-face-social-and-professional-stigma/2462175/Individuals with acne face social and professional stigma, and people with darker skin tones and more severe acne are disproportionately more likely to face greater stigma. These results, published in JAMA Dermatology, highlight the need to identify ways to
- UW's Simpson Lab Awarded $590K to Study Hailey-Hailey Diseasehttps://practicaldermatology.com/news/uws-simpson-lab-awarded-590k-to-study-hailey-hailey-disease/2462172/The Simpson Lab at the University of Washington has been awarded a three-year $590K grant by the LEO Foundation for ongoing research in Hailey-Hailey disease (HHD). Funding from this award will support Simpson Lab personnel and provide supplies for research aimed at investigating how mu
- AI in Action: Almirall, Barcelona Supercomputing Center, and Nostrum Biodiscovery Seek New Dermatologic Therapies via AIhttps://practicaldermatology.com/news/ai-in-action-almirall-barcelona-supercomputing-center-bsc-and-nostrum-biodiscovery-seek-new-dermatologic-therapies-via-ai/2462171/Almirall S.A. (BME: ALM), Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) and Nostrum Biodiscovery are joining forces to explore artificial intelligence (AI) and machine learning (ML) generative approaches to design new protein-protein modulators for dermatolo
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- Revealed: How Chronological Aging Affects EV Production by Human Keratinocyteshttps://practicaldermatology.com/news/revealed-how-chronological-aging-affects-ev-production-by-human-keratinocytes/2462166/Aging modulates extracellular vesicles of epidermal keratinocytes, new research in Aging suggests. The disturbance of intercellular communication is one of the hallmarks of aging. In their new study, researchers from